Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.80.

A number of research firms have weighed in on IMRX. Chardan Capital reissued a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research note on Wednesday, November 20th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a report on Thursday, November 14th.

Immuneering Stock Down 1.4 %

Immuneering stock opened at $2.05 on Wednesday. The company has a fifty day simple moving average of $2.21 and a 200-day simple moving average of $1.63. The firm has a market capitalization of $63.65 million, a price-to-earnings ratio of -1.04 and a beta of -0.40. Immuneering has a 52-week low of $1.00 and a 52-week high of $8.89.

Institutional Investors Weigh In On Immuneering

Institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $25,000. Corsair Capital Management L.P. purchased a new position in shares of Immuneering during the third quarter worth $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering in the second quarter valued at $44,000. XTX Topco Ltd raised its holdings in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in Immuneering during the 2nd quarter valued at about $67,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.